Indian Council of Medical Research - Rajendra Memorial Research Institute of Medical Sciences, Department of Clinical Medicine, Agamkuan, Patna, Bihar, India.
Lovely Professional University, Department of Pharmacology, Jalandhar - Delhi G.T. Road, Phagwara, Punjab, India.
Rev Soc Bras Med Trop. 2020 Dec 21;54:e20200208. doi: 10.1590/0037-8682-0208-2020. eCollection 2020.
Post-kala-azar dermal leishmaniasis is a skin disorder occurring in 5-10% of visceral leishmaniasis patients after treatment with miltefosine,the first-line drug for this skin disorder. We reported a case of acute anterior uveitis,a rare adverse effect, experienced by a patient treated with miltefosine for post-kala-azar dermal leishmaniasis. This adverse effect developed after 15 days of miltefosine consumption, and the patient himself discontinued the treatment. The ophthalmic complication was completely resolved with antibiotics and steroid eye drops. After recovery from the ophthalmic complication, the patient was successfully treated with liposomal amphotericin B for the skin lesions.
Post-kala-azar dermal leishmaniasis 是一种皮肤疾病，发生于 5-10%接受米替福新（治疗这种皮肤疾病的一线药物）治疗后的内脏利什曼病患者。我们报告了一例米替福新治疗 post-kala-azar dermal leishmaniasis 后出现的急性前葡萄膜炎，这是一种罕见的不良反应。该不良反应在米替福新治疗 15 天后出现，患者自行停药。眼部并发症经抗生素和皮质类固醇眼药水治疗后完全缓解。眼部并发症恢复后，患者成功地接受了脂质体两性霉素 B 治疗皮肤病变。
